Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers

Ročková, Veronika; Abbas, Saman; Wouters, Bas J.; Erpelinck, Claudia; Beverloo, H. Berna; Delwel, Ruud; Putten, Wim L.J. van; Löwenberg, Bob; Valk, Peter J.M.

doi:10.1182/blood-2011-02-334748

Cited by 107 publications

(80 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over 50% of CN-AML cases harbor an NPM1 mutation which, in the absence of FLT3/ITD mutations, 8 acts as an independent prognosticator for achieving complete remission and increased overall survival. [9][10][11] DNMT3A mutations are reported to be independently associated with a "less-favorable" outcome in CN-AML.…”

Section: Hoxa/pbx3 Knockdown Impairs Growth and Sensitizes Cytogenetimentioning

confidence: 99%

HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy

et al. 2013

View full text Add to dashboard Cite

show abstract

Section: Hoxa/pbx3 Knockdown Impairs Growth and Sensitizes Cytogenetimentioning

confidence: 99%

HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Myelodysplastic syndrome (MDS) with inv(3)/t(3;3) is also a rare aggressive disorder which occurs in less than 1% of all MDS cases and has a high risk of progression to AML. 2,6,7 The inv(3)/t(3;3) can occur rarely in other myeloid neoplasms, such as myeloproliferative neoplasms (MPN) including chronic myelogenous leukemia (CML), mostly during accelerated phase or in blast crisis, and overlap MDS/MPNs including chronic myelomonocytic leukemia. AML with inv(3)/t(3;3) is commonly refractory to conventional chemotherapy and has poor prognosis.…”

Section: Introductionmentioning

confidence: 99%

“…6,7,[12][13][14] Dysregulation of EVI1 plays an important role in stem cell self-renewal and leukemogenesis. Overexpression of EVI1 promotes myeloid cell proliferation and impairment of differentiation, and may be related to the adverse prognosis of myeloid neoplasms with inv(3)/t(3;3).…”

Section: Introductionmentioning

confidence: 99%

Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study

et al. 2014

View full text Add to dashboard Cite

“…[1][2][3][4][5] Many gene expression profiling studies have been performed in AML using DNA microarrays, [6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21] and the results have proven to be valuable in diagnosis, classification, and prognosis. [22][23][24] However, gene signatures from different laboratories are not always consistent.…”

Section: Introductionmentioning

confidence: 99%

Identification of a 24-Gene Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative Study

Herold

et al. 2013

JCO

Self Cite

176

175

View full text Add to dashboard Cite

A B S T R A C T PurposeTo identify a robust prognostic gene expression signature as an independent predictor of survival of patients with acute myeloid leukemia (AML) and use it to improve established risk classification. Patients and MethodsFour independent sets totaling 499 patients with AML carrying various cytogenetic and molecular abnormalities were used as training sets. Two independent patient sets composed of 825 patients were used as validation sets. Notably, patients from different sets were treated with different protocols, and their gene expression profiles were derived using different microarray platforms. Cox regression and Kaplan-Meier methods were used for survival analyses. ResultsA prognostic signature composed of 24 genes was derived from a meta-analysis of Cox regression values of each gene across the four training sets. In multivariable models, a higher sum value of the 24-gene signature was an independent predictor of shorter overall (OS) and event-free survival (EFS) in both training and validation sets (P Ͻ .01). Moreover, this signature could substantially improve the European LeukemiaNet (ELN) risk classification of AML, and patients in three new risk groups classified by the integrated risk classification showed significantly (P Ͻ .001) distinct OS and EFS. ConclusionDespite different treatment protocols applied to patients and use of different microarray platforms for expression profiling, a common prognostic gene signature was identified as an independent predictor of survival of patients with AML. The integrated risk classification incorporating this gene signature provides a better framework for risk stratification and outcome prediction than the ELN classification.

show abstract

Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers

Cited by 107 publications

References 55 publications

HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy

HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy

Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study

Identification of a 24-Gene Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative Study

Contact Info

Product

Resources

About